More than two years after Novartis parachuted in a temporary CEO for its troubled Korean branch, the Swiss drugmaker has tapped another temporary replacement. His key task? Grappling with ongoing kickback allegations.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,